In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Coronary pulse wave velocity a new biomechanics parameter that may explain FFR discrepancies.

Session Poster session 1

Speaker Pierre Lantelme

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : B Harbaoui (Lyon,FR), D Garcia (Lyon,FR), A Cividjian (Lyon,FR), O Muller (Lausanne,CH), PY Courand (Lyon,FR), P Lantelme (Lyon,FR)

B. Harbaoui1 , D. Garcia1 , A. Cividjian1 , O. Muller2 , P.Y. Courand1 , P. Lantelme1 , 1Civils Hospices of Lyon, cardiology - Lyon - France , 2University Hospital Centre Vaudois (CHUV) - Lausanne - Switzerland ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 187-188

Background: Taking into account coronary artery biomechanics is fundamental to understand the pathophysiology of myocardial perfusion. Coronary artery pulse wave velocity (CoPWV) is a new marker for assessing coronary artery stiffness using a pressure wire (J Am Heart Assoc. 2017). In the presence of a stenosis, the translesional pressure may be influenced by coronary artery stiffness. Fractional flow reserve (FFR) represents a common way to assess stenosis severity by evaluating translesional pressure ratio. It is thus conceivable that CoPWV may modulate translesional pressure ratio and thus FFR.

Aim: To study the independent impact of coronary arteries stiffness evaluated by CoPWV on FFR.

Methods: In 39 patients with an indication of FFR measurements on an intermediate coronary artery stenosis, CoPWV was evaluated. 58 coronary arteries were assessed. Associations were assessed by univariate correlations after log-transformation in case of skewed variables; independent predictors of FFR were assessed by multivariate linear regression including univariate determinants with p value<0.1.

Results: Patients characteristics were as follow: 29 (74.4%) men, 27 (69.2%) hypertensive, 16 (41%) diabetics, 25 (64.1%) smokers, 21 (53.8%) with a history of coronary artery disease. Mean FFR was 0.78±0.08. Mean coronary artery stenosis was 71±13%. Mean CoPWV was 10.4±6.3m/s. A better correlation was found between FFR and CoPWV (see figure) than between FFR and angiographic coronary stenosis severity, respectively r=0.514 p<0.001 and r=- 0.243 p=0.069. On the contrary, CoPWV didn't correlate with angiographic coronary stenosis severity.

Among all tested variables including, cardiovascular risk factors, angiographic coronary stenosis severity, reference vessel diameter, angiographic calcifications, systemic blood pressure and heart rate, CoPWV was the strongest independent predictor of FFR β=0.457 p<0.001. Angiographic coronary stenosis severity wasn't a determinant in multivariate analysis.

Conclusion: CoPWV is a strong determinant of FFR. This new parameter may influence the hemodynamic behavior of a stenosis. It may explain the discrepancies between anatomical and functional assessment of a coronary artery stenosis.

Correlation of FFR and LogCoPWV

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are